Showing 17,931 - 17,940 of 18,046
The focus of this paper is India. In line with TRIPS India has introduced a product patent regime in pharmaceuticals …
Persistent link: https://www.econbiz.de/10004988399
This paper makes several basic points relating to the economics of Intellectual Property Rights, the TRIPS Agreement …
Persistent link: https://www.econbiz.de/10005126702
are implemented in TRIPS and TRIPS+ agreements and I study the consequences for Developing Countries. …
Persistent link: https://www.econbiz.de/10005138907
pharmaceutical industries. Thus, governments should utilize TRIPS flexibilities and other regimes like price control to offset the …
Persistent link: https://www.econbiz.de/10005001271
Has upgrading and enforcing its patent laws slowed China’s economic growth? The answer we draw from detailed analysis of provincial aggregate data covering roughly the period 1990 through 2007 is strongly negative, but understanding the channels through which stricter protection of...
Persistent link: https://www.econbiz.de/10005033506
At the end of the 1990s, Brazil was faced with a potentially explosive HIV/AIDS epidemic. Through an innovative and multifaceted campaign, and despite initial resistance from multinational pharmaceutical companies, the government of Brazil was able to negotiate price reductions for HIV...
Persistent link: https://www.econbiz.de/10005680910
In the Trade-Related Intellectual Property Rights (TRIPS) Agreement of GATT (1 January 1995) it was agreed to harmonise …
Persistent link: https://www.econbiz.de/10005684357
geographical labelling may occur through geographical indications under the mandated trade rules of the TRIPS Agreement, trademarks …
Persistent link: https://www.econbiz.de/10005687120
Under certain conditions it is optimal for the noninnovating south to give patent protection for a longer time period than the innovating north. A cooperative patent agreement involves a larger protection by each country compared to the non-cooperative situation. [WP 9].
Persistent link: https://www.econbiz.de/10005487616
This paper highlights the status of the Indian biopharmaceutical industry and also makes a comparison with the global scenario. It also discusses the current situation regarding patenting biopharmaceuticals in India. [GIDR WP no. 168].
Persistent link: https://www.econbiz.de/10005487727